Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to increase awareness of prostate-specific antigen tests among travel insurers.

PSA tests are blood tests that measure the amount of prostate specific antigen (PSA) in blood. Raised levels, often in combination with other symptoms, can be an indication of prostate cancer, though not exclusively. PSA tests have previously been used as a screening tool in asymptomatic populations, but their limitations mean they are not currently recommended for population-level screening. To find better ways of testing for prostate cancer, the Government is investing £16 million into the Prostate Cancer UK-led TRANSFORM screening trial, which aims to identify more effective approaches for detecting prostate cancer earlier.

While the Department has no plans to target insurers with information about PSA, the NHS website has clear and accurate information about PSA testing that can be referred to. Where someone has had a PSA test and they are concerned about their travel insurance, they should discuss this directly with their insurers. Different insurers may take a different view of the relevant factors in determining the price of insurance.